Growth Metrics

Edwards Lifesciences (EW) Short term Debt (2017 - 2018)

Edwards Lifesciences has reported Short term Debt over the past 7 years, most recently at $599.2 million for Q2 2018.

  • For Q2 2018, Short term Debt changed N/A year-over-year to $599.2 million; the TTM value through Jun 2018 reached $599.2 million, changed N/A, while the annual FY2017 figure was $598.0 million, N/A changed from the prior year.
  • Short term Debt for Q2 2018 was $599.2 million at Edwards Lifesciences, roughly flat from $598.6 million in the prior quarter.
  • Over five years, Short term Debt peaked at $599.2 million in Q2 2018 and troughed at $2.2 million in Q3 2014.
  • A 3-year average of $307.0 million and a median of $319.8 million in 2017 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 80.15% in 2014 and fell as far as 80.15% in 2014.
  • Year by year, Short term Debt stood at $2.6 million in 2014, then soared by 22900.0% to $598.0 million in 2017, then increased by 0.2% to $599.2 million in 2018.
  • Business Quant data shows Short term Debt for EW at $599.2 million in Q2 2018, $598.6 million in Q1 2018, and $598.0 million in Q4 2017.